Filing Details

Accession Number:
0001261380-15-000023
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-03-18 18:39:32
Reporting Period:
2015-03-17
Filing Date:
2015-03-18
Accepted Time:
2015-03-18 18:39:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1006045 Iridex Corp IRIX Electromedical & Electrotherapeutic Apparatus (3845) 770210467
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1304121 Ronald Steckel 1212 Terra Bella Avenue
Mountain View CA 94043
Vp, Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-03-17 1,375 $3.86 32,089 No 4 M Direct
Common Stock Disposition 2015-03-17 1,375 $10.08 30,714 No 4 S Direct
Common Stock Acquisiton 2015-03-17 9,983 $3.99 40,697 No 4 M Direct
Common Stock Disposition 2015-03-17 9,983 $10.08 30,714 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Right to Buy Disposition 2015-03-17 1,375 $0.00 1,375 $3.86
Common Stock Stock Option Right to Buy Disposition 2015-03-17 9,983 $0.00 9,983 $3.99
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
13,750 2013-02-01 2017-01-01 No 4 M Direct
13,542 2003-04-16 2016-04-16 No 4 M Direct
Footnotes
  1. The sale reported in this Form 4 was pursuant to the Reporting Person's Rule 10b5-1 Selling Plan effective 12/5/14.
  2. The sales price reported in Column 4 of Table 1 represents the weighted average sale price of the shares sold, ranging from $10.00 to $10.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. This option was granted pursuant to IRIDEX Corporation's 2008 Equity Incentive Plan and is exempt to Rule 16b-3.
  4. The shares are subject to vesting according to the following schedule: 1/48th of the total number of shares vest each month.
  5. The shares shall vest as follows: 12/48ths of the shares shall vest 12 months after the Vesting Commencement Date and 1/48th of the shares shall vest each month thereafter.